Omega Diagnostics logo

ODX - Omega Diagnostics Share Price

67p -2.5  -3.6%

Last Trade - 29/05/20

Sector
Healthcare
Size
Small Cap
Market Cap £100.9m
Enterprise Value £104.2m
Revenue £9.00m
Position in Universe 911th / 1825
Bullish
Bearish
Unlock ODX Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Financial Summary
FINANCIAL BRIEF: : For the six months ended 30 September 2019, Omega Diagnostics Group Plc revenues increased 6% to £4.5M. Net loss before extraordinary items decreased 19% to £321K. Revenues reflect Food Intolerance segment increase of 8% to £4.2M, Allergy and Autoimmune segment increase of 44% to £301K, Africa/Middle East segment increase of 43% to £525K, Europe segment increase of 9% to £1.5M, India segment increase of 15% to £404K.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ODX Revenue Unlock ODX Revenue

Net Income

ODX Net Income Unlock ODX Revenue

Normalised EPS

ODX Normalised EPS Unlock ODX Revenue

PE Ratio Range

ODX PE Ratio Range Unlock ODX Revenue

Dividend Yield Range

ODX Dividend Yield Range Unlock ODX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ODX EPS Forecasts Unlock ODX Revenue
Profile Summary

Omega Diagnostics Group PLC is a medical diagnostics company. The Company's segments are Allergy and Autoimmune; Food Intolerance; Infectious/Other, and Corporate. Its product categories include allergy, anemia, autoimmunity, fertility and growth hormones, food intolerance, infectious disease, inflammation, quality control, thyroid hormones and tumor markers. For allergy, it offers Allergodip, which is an enzyme immunoassay for the semi-quantitative determination of Specific immunoglobulin E (IgE) in serum or plasma. For anemia, it offers ATHOZYME Ferritin, which is an enzyme-immunoassay (ELISA) test for the detection and quantification of Ferritin in human serum. It offers a range of products for Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE), Antiphospholipid Syndrome (APS), Connective Tissue Disease, Gastrointestinal, and Vasculitis and Renal Disease. Its Fertility Hormones products include PATHOZYME-LH (Luteinizing Hormone), PATHOZYME-Prolactin and PATHOZYME-Oestradiol.

Directors
Last Annual March 31st, 2019
Last Interim September 30th, 2019
Incorporated January 16, 2004
Public Since March 18, 2004
No. of Shareholders: n/a
No. of Employees: 152
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Shares in Issue 273,797,650
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ODX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ODX
Upcoming Events for ODX
Wednesday 21st October, 2020 Estimate
Omega Diagnostics Group PLC Annual Shareholders Meeting
Frequently Asked Questions for Omega Diagnostics
What is the Omega Diagnostics share price?

As of 29/05/20, shares in Omega Diagnostics are trading at 67p, giving the company a market capitalisation of £100.9m. This share price information is delayed by 15 minutes.

How has the Omega Diagnostics share price performed this year?

Shares in Omega Diagnostics are currently trading at 67p and the price has moved by 0.554k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Omega Diagnostics price has moved by 0.646k% over the past year.

What are the analyst and broker recommendations for Omega Diagnostics?

Of the analysts with advisory recommendations for Omega Diagnostics, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Omega Diagnostics is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will Omega Diagnostics next release its financial results?

Omega Diagnostics is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2020-09-30
What is the Omega Diagnostics dividend yield?

Omega Diagnostics does not currently pay a dividend.

Does Omega Diagnostics pay a dividend?

Omega Diagnostics does not currently pay a dividend.

When does Omega Diagnostics next pay dividends?

Omega Diagnostics does not currently pay a dividend.

How do I buy Omega Diagnostics shares?

To buy shares in Omega Diagnostics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Omega Diagnostics?

Shares in Omega Diagnostics are currently trading at 67p, giving the company a market capitalisation of £100.9m.

Where are Omega Diagnostics shares listed? Where are Omega Diagnostics shares listed?

Here are the trading details for Omega Diagnostics:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: ODX
What kind of share is Omega Diagnostics?

Based on an overall assessment of its quality, value and momentum, Omega Diagnostics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Omega Diagnostics share price forecast 2020?

Shares in Omega Diagnostics are currently priced at 67p. At that level they are trading at 62.69% premium to the analyst consensus target price of 41.18.

Analysts covering Omega Diagnostics currently have a consensus Earnings Per Share (EPS) forecast of -0.005 for the next financial year.

How can I tell whether the Omega Diagnostics share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Omega Diagnostics. Over the past six months, the relative strength of its shares against the market has been 0.687k%. At the current price of 67p, shares in Omega Diagnostics are trading at 0.273k% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Omega Diagnostics PE Ratio?

We were not able to find PE ratio data for Omega Diagnostics.

Who are the key directors of Omega Diagnostics?

Omega Diagnostics's management team is headed by:

Kieron Harbinson - FID
Iain Logan - CTR
Jag Grewal - EDR
Karsten Brenzke - OTH
Colin King - CEO
Mike Gordon - OTH
Edward Valente - OTH
Jeremy Millard - NID
William Rhodes - NEC
Jamie Yexley - OTH
Prashant Maniar - OTH
Who are the major shareholders of Omega Diagnostics?

Here are the top five shareholders of Omega Diagnostics based on the size of their shareholding:

Sneller (Richard Edgar) Individual Investor
Percentage owned: 17.64% (26.6m shares)
Legal & General Investment Management Ltd. Investment Advisor/Hedge Fund
Percentage owned: 7.74% (11.7m shares)
Evans (David Eric) Individual Investor
Percentage owned: 3.76% (5.65m shares)
SG Private Banking (Suisse) S.A. Bank and Trust
Percentage owned: 2.85% (4.29m shares)
Unicorn Asset Management Ltd. Investment Advisor
Percentage owned: 2.83% (4.27m shares)
Similar to ODX
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.